Latest Intellectual Property News

Vection Technologies has reported a milestone positive net cash flow in its traditionally weak quarter, driven by a 60% half-on-half revenue surge and strategic acquisition integration.

First Graphene has secured key patents for its Kainos Technology in Australia and Korea, positioning itself at the forefront of producing graphite, graphene, and hydrogen from petroleum waste. This milestone aligns with growing global demand for critical minerals essential to the energy transition.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

K-TIG Limited is set to transform its business with a $7–10 million capital raise to acquire US-based Metal Powder Works, issuing performance-based vendor shares that an independent expert deems fair and reasonable.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

BOD Science has executed an asset sale deed transferring critical intellectual property rights to Optimus Salvus, marking a pivotal step in its Deed of Company Arrangement process.

Sparc Technologies has committed to Stage 2 of its hydrogen joint venture, secured a pioneering patent in Morocco, and progressed graphene additive trials, signaling momentum in its clean energy and materials innovation.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

BPH Global has completed its acquisition of Indonesian seaweed assets, establishing a wholly owned subsidiary and launching joint operations aimed at expanding seaweed cultivation and bio-stimulant product development across Asia.